ArticleFrontiers in public health2025
Global, regional, and national burden of cardiovascular diseases attributable to secondhand smoke, 1990-2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study assessed the global burden and trends of cardiovascular diseases attributable to secondhand smoke (CVD-SHS) from 1990 to 2021. Methods: The global burden of disease (GBD) database was utilized to analyze estimated annual percentage change (EAPC), age-standardized mortality rates (ASMR), age-standardized DALY rates (ASDR), disability-adjusted life years (DALYs), and deaths due to CVD-SHS. Subsequently, further analysis was conducted by region, age group, sex, and socio-demographic index (SDI). Finally, Spearman correlation analyses were used to assess the correlation of ASDR and ASMR with SDI. Results: From 1990 to 2021, global CVD-SHS deaths and DALYs increased by 34.5 and 23.1%, respectively, while ASMR and ASDR decreased by 41.8 and 42.0%. In 2021, CVD-SHS deaths totaled 694,692 (ASMR 8.31/100,000), with DALYs at 16,674,552 (ASDR 194.59/100,000). Regionally, the highest ASDR and ASMR were observed in low-middle and middle SDI regions, with minimal reductions in low SDI regions. Correlation analysis indicated that ASMR and ASDR, as well as their EAPCs, were negatively correlated with SDI. Moreover, CVD-SHS burden was higher in males and older age groups, predominantly affecting those aged 35 and above in lower SDI regions, and those aged 65 and above in high SDI regions. Conclusion: From 1990 to 2021, the global, regional, and national burden of CVD-SHS showed a paradoxical trend: while ASMR and ASDR declined, the absolute number of deaths and DALYs continued to rise. The burden and its growth rate were negatively correlated with SDI, with the highest impacts observed in low- and middle-SDI regions, males, and older populations. Moreover, stroke-SHS showed a stronger negative correlation with SDI than IHD-SHS, suggesting subtype-specific disparities. These findings highlight the persistent and uneven burden of CVD-SHS worldwide and underscore the need for targeted, region- and disease-specific prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.